LogoFDA 510(k) Search
Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K152365
    Device Name
    AgaMatrix Jazz Wireless 2 Blood Glucose Monitoring System
    Manufacturer
    AgaMatrix, Inc.
    Date Cleared
    2016-04-21

    (244 days)

    Product Code
    NBW,CGA
    Regulation Number
    862.1345
    Type
    Traditional
    Panel
    Clinical Chemistry
    Reference & Predicate Devices
    K103544,K132821
    Why did this record match?
    Device Name :

    AgaMatrix Jazz Wireless 2 Blood Glucose Monitoring System

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    The AgaMatrix Jazz™ Wireless 2 Blood Glucose Monitoring System is intended for the quantitative measurement of blood glucose (sugar) levels in fresh capillary whole blood samples drawn from the fingertip. It is intended to be used by a single patient and should not be shared. The AgaMatrix Jazz ™ Wireless 2 Blood Glucose Monitoring System is intended for selftesting outside the body (In vitro diagnostic use) by people with diabetes at home as an aid to monitor the effectiveness of diabetes control. The AgaMatrix Jazz™ Wireless 2 Blood Glucose Monitoring System is not for the diagnosis of, or screening for diabetes, and is not intended for use with neonates.

    The AgaMatrix Jazz™ Blood Glucose Test Strips are for use with the AgaMatrix Jazz™ Wireless 2 Blood Glucose Meter to quantitatively measure glucose (sugar) in fresh capillary whole blood samples drawn from the fingertip.

    Device Description

    The AgaMatrix Jazz™ Wireless 2 Blood Glucose Monitoring System includes the AgaMatrix Jazz™ Wireless 2 Blood Glucose Meter and the AgaMatrix Jazz™ Blood Glucose Test Strips. The apply blood symbol is displayed for the user to apply blood to the test strip until the meter begins the test. When enough blood has been applied to the strip electrodes the meter detects trigger current from the test strip initiating the test countdown. When the countdown is complete a test result is displayed on the meter screen. The unit of measure displayed on the meter screen is fixed in mg/dL and cannot be modified by the user.

    The following items are included in the AgaMatrix Jazz™ Wireless 2 Blood Glucose Monitoring System:

    • 1 AgaMatrix Jazz™ Wireless 2 Glucose Meter .
    • . 1 Owner's Guide
    • . 1 Carry Case
    • 1 AgaMatrix Lancing Device .
    • . 10 AgaMatrix Lancets
    • AgaMatrix Jazz™ Blood Glucose Test Strips -
    • -1 Meter Pairing & Syncing Guide

    The following items are compatible with the AgaMatrix Jazz™ Wireless 2 Glucose Monitoring System and are available separately:

    • . AgaMatrix Glucose Control Solutions (cleared in K103544)
    • AgaMatrix Diabetes Manager Mobile Application (cleared in K132821) -
    AI/ML Overview

    Here's a summary of the acceptance criteria and the study details for the AgaMatrix Jazz Wireless 2 Blood Glucose Monitoring System, extracted from the provided document:

    1. Table of Acceptance Criteria and Reported Device Performance

    The document doesn't explicitly state "acceptance criteria" in a single consolidated table with corresponding performance. However, based on the Performance Characteristics section, the implicit acceptance criteria are derived from standard deviations, coefficients of variation (CV%), and percentages of agreement within certain error ranges when compared to a reference method (YSI 2300 Glucose Analyzer).

    Analytical Performance (Precision/Reproducibility):

    Glucose Concentration (mg/dL)Acceptance Criteria (Implicit from Industry Standards/FDA Guidance)Reported Device Performance (CV%)
    30-50Not explicitly stated, but generally low CV% is desiredCombined: 9.0% (SD: 2.9 mg/dL)
    51-110Not explicitly stated, but generally low CV% is desiredCombined: 4.3% (SD: 4.2 mg/dL)
    111-150Not explicitly stated, but generally low CV% is desiredCombined: 3.2% (SD: 4.1 mg/dL)
    151-250Not explicitly stated, but generally low CV% is desiredCombined: 3.5% (SD: 7.7 mg/dL)
    251-400Not explicitly stated, but generally low CV% is desiredCombined: 4.0% (SD: 15.3 mg/dL)
    Intermediate Precision
    Control Level 1 (57 mg/dL)Not explicitly stated, but generally low CV% is desiredLot 1: 2.8%, Lot 2: 3.7%, Lot 3: 3.1%
    Control Level 2 (134-137 mg/dL)Not explicitly stated, but generally low CV% is desiredLot 1: 2.6%, Lot 2: 2.1%, Lot 3: 2.3%
    Control Level 4 (342-345 mg/dL)Not explicitly stated, but generally low CV% is desiredLot 1: 2.5%, Lot 2: 2.6%, Lot 3: 2.2%

    Method Comparison (System Accuracy) with YSI Reference:

    This part of the study is crucial for demonstrating device accuracy against a recognized standard. The acceptance criteria for blood glucose monitoring systems are typically based on ISO 15197:2013, which specifies accuracy requirements. Although the document doesn't explicitly refer to ISO 15197, the presentation of results in terms of percentage agreement within specific limits (e.g., ±5 mg/dL, ±15%) aligns with these standards.

    Glucose ConcentrationAcceptance Criteria (Implied based on typically adopted standards for BGMS)Reported Device Performance (Combined)
    **
    Ask a Question

    Ask a specific question about this device

    Page 1 of 1